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Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hemato-
poietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by
donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to
play an important role. Recent studies from several laboratories have enhanced our understanding of how
donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr
Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activation and loss
of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have
identiﬁed novel B celledirected agents that may be effective for prevention or treatment of cGVHD. Some B
celledirected therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of
these studies documenting the potential efﬁcacy of this approach. Supported by mechanistic studies in pa-
tients and preclinical models, new B celledirected therapies for cGVHD will now be evaluated in clinical trials.
 2015 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) after alloge-
neic hematopoietic stem cell transplantation (HSCT) con-
tinues to be a common, debilitating, and deadly complication
of therapy. Despite improved tools for diagnosis and clinical
assessment of disease activity, cGVHD pathophysiology
remains ill deﬁned and this has hampered the development
of effective new therapies [1,2]. In this regard, analysis of
patient blood and tissue samples and new murine models
of cGVHD have expanded our knowledge of disease patho-
genesis and the complexity of mechanisms that lead to tissue
damage [3]. Although donor T cells clearly play a critical role
in the initiation and maintenance of allo-immunity, many
laboratory and clinical studies have shown that donor B cells
also play an important role in the pathophysiology of cGVHD
[4-6]. Importantly, therapeutic strategies targeting B cells
can provide clinical beneﬁt in many patients with active
cGVHD [7].x.doi.org/10.1016/j.bbmt.2014.10.029.
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standing of the role of B cells in cGVHD. A series of new
studies in HSCT patients and murine models have begun to
elucidate the role of B cells in the pathogenesis and persis-
tence of cGVHD and this has led to the evaluation of new
therapeutic approaches speciﬁcally targeting aspects of B cell
reconstitution and function after HSCT. As these new thera-
peutic approaches are evaluated and integrated with other
established therapies, we anticipate that new therapeutic
agents will lead to signiﬁcant improvement in the long-term
outcome of patients with cGVHD.
B CELL ACTIVATION PATHWAYS IN CHRONIC GVHD
In healthy individuals, B cell development is a dynamic,
daily process with a high propensity for the formation of self-
reactive B cells. Despite central B cell tolerance mechanisms,
a remarkably large pool of polyreactive and potentially auto-
reactive B cells arise at a constant rate from bone marrow
(BM) precursor cells [8]. Receptor editing, deletion, and
anergy induction in the BM [9-11] do not eliminate all
potentially auto-reactive B cell clones, and it has been esti-
mated that 55% to 75% of transitional B cells emerging from
BM in healthy adults are self-reactive [8,12]. The mainte-
nance of normal B cell immunity, therefore, requires deletion
of auto-reactive clones coupled with positive selection after
encounter with microbes (or other foreign antigens) [13]. In
conjunction with B cell receptor (BCR) signaling, B
celleactivating factor (BAFF) plays an important role inood and Marrow Transplantation.
Figure 1. BAFF and antigen-driven B cell activation. In cGVHD, B cells are promoted by antigen and excessive BAFF levels to survive and produce antibodies.
Constitutive antibody production by certain B cell subsets in cGVHD may directly mediate pathology. B cells may also serve as antigen presenting cells (APC).
S. Sarantopoulos et al. / Biol Blood Marrow Transplant 21 (2015) S11eS18S12determining B cell fate/survival. In acquired autoimmune
diseases, abnormally high levels of BAFF subvert the devel-
opment of B cell tolerance by attenuating BCR-triggered
apoptosis of polyreactive B cells. In self-reactive BCR trans-
genic murine models, limiting amounts of BAFF are required
to promote B cell turnover and avoidance of auto-reactivity
[14,15]. Early after HSCT, the peripheral B cell compartment
likely comprises recent BM emigrants consisting of short-
lived transitional cells. Although these cells are capable of
primary immune reactions and generate short-lived plasma
cells, they do not take part in the germinal center (GC)
reaction. This likely explains why B cell populations after
HSCT have a relatively low diversity of antigen binding sites
(ie, BCRs) with a high frequency of low-afﬁnity, potentially
allo- or auto-reactive antibodies. As BAFF levels are high after
HSCT, B cells that are not deleted through negative selection
are likely positively selected during B cell recovery. Although
speciﬁc antigen targets remain largely unknown, high-
throughput BCR sequencing of B cell subsets suggests that
the IgG CDR3s comprise poly- and auto-reactive character-
istics [16]. These data, along with frequent production of
auto-antibodies [17-19], suggest a critical breakdown in pe-
ripheral B cell tolerance in patients with cGVHD. Taken
together, these ﬁndings suggest a model for aberrant
persistence of allo- and auto-reactive B cells after trans-
plantation, shown in Figure 1. In this model, we hypothesize
that as B cells develop after HSCT, there is a failure of normal
B cell tolerance checkpoints, at least in part due to high
levels of BAFF. As a result, there is persistence of donor B
cells reactive to a variety of recipient antigens and secretion
of pathologic allo- and auto-antibodies.
In the presence of a large, diverse, mature B cell pool,
normal B cells consume and sequester BAFF, and auto-
reactive B cell clones that require high levels of BAFF are
unable to survive [20]. After allogeneic HSCT, persistently
elevated BAFF levels are associated with B lymphopenia and
cGVHD development [5,21]. In contrast, supranormal B cell
numbers are found in patients without cGVHD [21,22].
Because B cells in patients without cGVHD have high levels
of BAFF receptors, these cells are able to sequester BAFF and
prevent high levels of BAFF from promoting auto-reactive
B cell clones [23]. This hypothesis is supported by the
ﬁnding that patients unable to robustly recover their B cell
compartment may not respond to rituximab, and BM pro-
duction of B cells early after HSCT may be critical for
prevention of cGVHD [21,22,24,25]. In addition to mature
B cells that compete for BAFF, IL-10eproducing regulatory B
cells may play an important role in the prevention of cGVHD
[26]. IL-10eproducing cells are present in higher proportions
in patients without cGVHD [27]. Our data indicate a role for
altered B cell homeostasis in cGVHD pathogenesis and reveal
a limitation of anti-CD20, rituximab, therapy after HSCT [28].
How the B cell compartment is skewed toward robustmature B cell recovery and perhaps IL-10 production requires
further study.
To determine if B cells are activated in cGVHD, we
examined unstimulated B cell lysates for signaling pathways
known to be downstream of BAFF. B cells in cGVHD showed
evidence of increased metabolic activity and survival, with
enhanced signaling via the AKT and ERK pathways [29]. BIM
knockout mice have an autoimmune phenotype that is in-
dependent of BAFF, and BIM counteracts BAFF signaling [30].
Accordingly, excess BAFF reduces BIM levels in transgenic
BCR auto-reactive murine B cells [31]. Although increased
AKT and ERK signaling may be BCR-dependent, proapoptotic
BIM is also increased after BCR engagement unless counter-
acted by BAFF. Consistent with BAFF-associated AKT and ERK
signaling, we found BIM isoforms were decreased in cGVHD
B cells [32]. Thus, similar to what is found in autoimmune
mice, high BAFF levels may rescue intermediate afﬁnity, self-
reactive B cells during recovery after HSCT by attenuating
apoptosis of recirculating B cells after GC reactions [14,15].
Chronic exposure to BAFF results in hypermetabolic,
enlarged B cells, capable of constitutive auto-antibody pro-
duction [33]. It is therefore tempting to directly link exces-
sive BAFF levels to B cell activation in cGVHD
pathophysiology, but this link remains to be determined.
In addition to BAFF, B cell activation and survival depend
on the afﬁnity and speciﬁcity for antigen and on coreceptor
molecule binding for conveyance of positive or negative BCR
signals [34]. We have begun to investigate this further in
cGVHD to identify potential therapeutic molecular targets. In
healthy mice, BAFF sets the threshold for BCR-mediated
selection among naïve, mature B cells [35]. In the absence
of BAFF, tonic or chronic stimulation with antigen results in
constant signaling through the BCR, leading to anergy or
death [34]. In the setting of constant exposure to foreign
(or allo) antigens and excessive BAFF, B cell hyper-
responsiveness to antigen may contribute to cGVHD patho-
genesis. Using anti-IgM as a surrogate for soluble antigen, we
found that cGVHD B cells not only responded more robustly
after exposure, but that this response was associated with
increased protein levels of the proximal BCR machinery
molecules spleen tyrosine kinase (SYK) and B cell linker
protein (BLNK) [36]. Proliferation after antigen engagement
has been mechanistically linked to both BAFF-R and BLNK
[37,38]. Signaling after BCR engagement by antigen entails
phosphorylation and activation of the tyrosine kinase SYK,
which subsequently phosphorylates and activates the
tyrosine-rich adapter protein BLNK that is then recruited to
the BCR signalosome. BLNK is central to further downstream
signaling, as it also acts as a docking protein for Bruton’s
tyrosine kinase (BTK), PLCg2, and the other crucial BCR
complex signaling molecules. We found that this heightened
activation via BCR was abrogated by the SYK inhibitor fos-
tamatinib [36], suggesting potential clinical utility of this
Figure 2. Development and persistence of potentially pathological cGVHD B cells. Altered B cell homeostasis with high BAFF to naïve B cell ratios after HCT leads to
persistence of aberrantly activated B cells. Decreased bone marrow output and production of immature (and potentially of B10) B cells leads to excessive levels of
BAFF, sufﬁcient to support potentially pathological B cell subsets.
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collaboration with Dr. Blazar’s lab have also shown the
importance of BCR signaling and the ability of SYK inhibition
to reverse tissue damage associated with cGVHD. Together,
our data suggest that BCR signaling after antigen engage-
ment during B cell reconstitution after HSCT is likely critical
for persistence of auto-reactive B cells, and selective inhibi-
tion of BCR signalingmay provide a new therapeutic target in
patients with cGVHD.
Although genetic disparity between donor and recipient
must exist for cGVHD to develop, transferable T cell
auto-reactivity occurs after allo-reactivity in murine models
[39-41]. In patients, antibodies to both allo-antigens and to
nonpolymorphic (“auto”) antigens are also found. For
example, a coordinated T-B response to disparate epitopes on
the minor histocompatibility antigen DBY has been
described [42,43]. T cells remain crucial effector cells in this
disease [44], and although B-T coordinated responses have
been delineated [42,43], whether B cells drive T cell re-
sponses remains unclear. Antibodies to polymorphic and
nonpolymorphic recipient antigens have been associated
with cGVHD [4,17,18]. In addition to other B cell functions
[40,45,46], secreted antibodies likely play a role in cGVHD
tissue destruction, since Ig deposits have been observed in
lesional skin tissue [6,47]. Likewise, antibody productionwas
recently shown in a murine model to be required for cGVHD
development [6]. Studies in other diseases demonstrate the
role of antibodies in cross-presentation to T effector cells
[48,49]. Thus, allo- and auto-antibodies may facilitate the
cross-presentation of antigens to T effector cells, thereby
amplifying T cell responses to minor histocompatibility
antigen or auto-antigens [49,50]. Unrestrained T follicular
helper (TFH) cells have been associated with loss of B cell
tolerance, potentially in abnormal GC reactions [51,52]. In
mice, TFH cells are vital for increased GC responses and for
cGVHD genesis [53]. In patients, GC composition is altered,
but whether TFH cells promote aberrant B cells is an area of
active investigation. Cell surface CD27 increases after B cells
encounter antigen. We found that circulating CD27þ B cells
from cGVHD patients constitutively produce IgG without the
requirement of further BCR or second signal stimulation [5].
These cells also have a distinct gene expression proﬁle
compared with healthy CD27þ B cell counterparts [32]. In
patients, both pre-GC and post-GC peripheral blood B cell
subsets occur in increased proportions, and these increaseswere associated with augmented levels of plasma BAFF [5].
Thus, unlike the antimicrobial memory response of healthy
individuals, cGVHD CD27þ B cells potentially mediate anti-
normal recipient tissue responses, although further study is
required to afﬁrm and quantify the pathologic potential of
these cells [54,55].
Together, our data have allowed us to develop a working
model for potentially disease-mediating B cell development
after HSCT (Figure 2). As aberrantly activated cells represent
potential therapeutic targets, further studies of B cell
signaling in patients with cGVHD are clearly needed. Pursuit
of hypothesis-driven studies of human B cell function will
advance our understanding of cGVHD pathophysiology and
will lead to development of clinical trials aimed at preven-
tion and treatment.
PRECLINICAL MODELS EVALUATING NOVEL B
CELLeDIRECTED THERAPIES FOR CHRONIC GVHD
Preclinical development of new therapeutic modalities
for cGVHD has been hindered by models with pathologic
ﬁndings that may not simulate the development of human
cGVHD. We developed a multi-organ system model of
cGVHD induced by allogeneic HSCT after a conditioning
regimen of cyclophosphamide and total body radiation. In
this model, cGVHD manifestations are observed in a wide
spectrum of target organs (lung, liver, spleen, thymus, colon,
tongue) [6,56]. Fibrosis was demonstrated in the lung and
liver and was associated with CD4þ T cells, B220þ B cell
inﬁltration, and IgG2c class-switched antibody deposition
[6]. Lung ﬁbrosis resulted in pulmonary dysfunction and
airway obliteration, which leads to bronchiolitis obliterans
syndrome (BOS), pathognomonic for cGVHD of the lung.
Antibody secretion from BM-derived B cells was essential for
cGVHD, as evidenced by the lack of disease when using BM
incapable of producing B cells or secreted polyclonal IgG.
GCs, critical for efﬁcient class switching and antibody
secretion, were signiﬁcantly increased in size and number in
cGVHD mice [6]. cGVHD maintenance was dependent upon
GC formation, as infusion of a lymphotoxin-receptor-
immunoglobulin fusion protein into mice with established
cGVHD reduced GCs and suppressed BOS measured by
pulmonary function tests.
GCs are formed by cooperation between a subset of T and
B cells known as TFH cells and GC B cells, respectively.
Recently, we reported that increased frequency of TFH cells
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patients, the anti-CD20 mAb, rituximab, can prevent steroid-
requiring chronic GVHD as assessed in a phase 2 trial [57]
and results in amelioration of cGVHD in patients, especially
those with skin and mucosal involvement [7]. However, not
all patients respond and not all responses are permanent.We
have found that administering a highly depleting anti-CD20
mAb to mice with established cGVHD resulted in peripheral
B cell depletion, but B cells remained in the lung, BOSwas not
reversed [53], and cGVHD manifestations remained [58].
Instead, BOS could be treated by eliminating production of
IL-21 by donor T cells or IL-21 receptor (IL-21R) signaling of
donor B cells. Blocking mAbs for TFH-GC B cell interactions,
including IL-21/IL-21R, inducible T cell costimulator/induc-
ible T cell costimulator ligand, and CD40L/CD40, hindered GC
formation and cGVHD, indicating a role for TFH and GC B
cells and suggesting a new line of therapy to reverse cGVHD.
To study transcriptional pathways and develop targeted
therapeutics for cGVHD, we studied the effects of emerging
therapeutic agents targeting GCs. BCL6 is a master regulatory
transcription factor that facilitates GC development in a
cooperative manner with emerging chromatin-associated
factors, namely the EZH2 lysine methyltransferase and the
BRD4 epigenetic reader protein [59,60]. To determine
whether strategies that disrupt GC integrity could be used to
treat cGVHD we targeted BCL6 using a direct-acting ligand,
79-6; [61,62], EZH2 using 3 structurally distinct inhibitors
(JQ-E, UNC1999 [63] and DZNep [64]); and a ﬁrst-in-class
BRD4 inhibitor, JQ1 [60,65]. In T cells, Bcl6 is selectively
expressed in TFH and GC Tregs. We observed a 10-fold
increase in percent of splenic BCL6þ T cells in cGVHD mice.
The small molecule BCL6 inhibitor 79-6 was synthesized and
used to treat mice with active cGVHD. Treatment reversed
BOS and resulted in a decrease in GC B cells and lung
collagen. EZH2 catalyzes the methylation of lysine 27 on
histone 3 (H3K4me3) silencing genes to a transcriptionally
repressive state. EZH2 is markedly upregulated during the
GC reaction and prevents GC B cell terminal differentiation,
allowing afﬁnity maturation to occur [62,66,67]. Selective
EZH2 deletion in either BM-derived B cells or splenic T cells
completely prevented cGVHD with a decrease in GC fre-
quency. Whereas naïve T cells express low EZH2 levels, EZH2
is rapidly upregulated upon allo-stimulation.We compared 3
drugs that reduce H3K4me3, 2 pyridinone inhibitors (JQ-E
and UNC1999) and DZNep, which destabilizes EZH2 com-
plexes. At established doses, DZNep and UNC1999 were
ineffective or toxic, respectively. In contrast, JQ-E fully
reversed cGVHD lung dysfunction and ﬁbrosis around the
bronchioles was signiﬁcantly decreased.
JQ1 is a ﬁrst-in-class epigenetic reader that recognizes
histone modiﬁcations and has been shown to reduce B cell
lymphomas via inhibiting super-enhancereassociated tran-
scripts and to treat cardiac failureeinduced ﬁbrosis. JQ1
administration to cGVHD mice signiﬁcantly inhibited BOS
and collagen deposition. Taken together, these data demon-
strate for the ﬁrst time the critical role of BCL6 and targeting
of histones that affect the transcriptional repressive states
via EZH2 and a BET bromodomain epigenetic reader. These
data also provide a strong foundation for clinical trials of
inhibitors that directly or epigenetic modiﬁers and readers
that indirectly target BCL6.
Given our data on TFH produced IL-21 in cGVHD, we
tested a Rho-associated kinase 2 inhibitor, KD025, that
blocks IL-21 production [68,69] and has been shown safe in
normal healthy volunteers. KD025 inhibits STAT3phosphorylation, which supports Th17 generation and IL-21
production, each of which we have linked to cGVHD gener-
ation in our model. Concurrently, KD025 increases STAT5
phosphorylation and regulatory T cell suppressor function in
a dose-responsive fashion. KD025 treatment shifts Th17/
regulatory T cell balance. KD025-treated cGVHD mice had a
dose-dependent decrease in the development of pathogenic
pulmonary function, which correlated with a marked
reduction of antibody deposition in the lungs compared with
non-cGVHD controls, along with a decrease in collagen
deposition in the lungs and GCs. We demonstrated that mice
that underwent transplantation with inducible STAT3-
deﬁcient T cells or BM cells had pulmonary function com-
parable to the healthy controls, suggesting that STAT3 is a
potential therapeutic target in both T and B cells and is
necessary for the development of cGVHD.
Many of the cellular activation and effector functions of
Th17 and TFH cells can be attributed to BTK and IL-2 induc-
ible kinase (ITK) [70,71] and antibody production by GC B
cells depends upon BTK [71]. Ibrutinib is a ﬁrst-in-class
irreversible inhibitor of BTK and ITK that blocks down-
stream immune receptor activation [72-74]. Because ibruti-
nib can block the activation of B cells via BTK inhibition as
well as speciﬁc T-helper subsets that drive the development
of cGVHD via ITK inhibition, we hypothesized that it may be
ideally suited to the treatment of cGVHD. We show that
ibrutinib treatment reversed TFH-GCedependent cGVHD
and BOS, associated with blockade of GC formation and
reduction of antibody deposition and ﬁbrosis. Additionally,
ibrutinib ameliorated the progression of cGVHD in a minor
antigen, T celledependent murine model of sclerodermatous
cGVHD, reducing skin lesions, hair loss, and lymphohistio-
cytic inﬁltration [75]. These data strongly support the clinical
investigation of ibrutinib as a novel therapeutic strategy for
the treatment of cGVHD.
SYK is activated by BCR engagement. After antigen-BCR
engagement, SYK is phosphorylated at Y348, allowing for B
cell survival and proliferation. Increased proximal BCR
signaling was recently described in cGVHD patient B cells
[36]. We now demonstrate that SYK was hyperactive in B
cells during cGVHD and that SYK expressionwas necessary in
B but not T cells for murine cGVHD progression. We found
that total B cell frequency in mice receiving SYK knock-out
(KO) BM was decreased 8-fold, whereas T cell frequency was
unaffected. These data are consistent with the dependency of
activated B cells on SYK for proliferation and survival and a
requirement for activated donor-derived BM B cells in
cGVHD pathogenesis [6,53].
Fostamatinib is a potent small molecule inhibitor of SYK.
Studies in rheumatoid arthritis have demonstrated efﬁcacy
with fostamatinib in randomized phase II clinical trials
[76,77]. Mice receiving fostamatinib for cGVHD treatment
had restoration of pulmonary function, similar to the healthy
controls that had undergone transplantation, along with a
reduced number of GC reactions in the spleen associated
with a decrease in frequency of splenic GC B cells. To deter-
mine if human cGVHD B cells are more susceptible to SYK
blockade, B cells puriﬁed from human peripheral blood were
treated in vitro with R406, the active form of R788. B cells
from patients with cGVHD had increased apoptosis
compared with patients without cGVHD after R406, consis-
tent with work by Allen et al. [36] that revealed that R406
preferentially kills cGVHD B cells via apoptosis. Together,
these data now demonstrate that constitutively activated B
cells can be selectively targeted in cGVHD.
Table 1
Monoclonal Antibodies, Drugs, and Their Targets Used to Treat Established
cGVHD in Mice
Agent Target
Anti-IL21 IL21/IL21R
Anti-ICOS ICOS/ICOSL
Anti-CD40L CD40/CD40L
79-6 BCL6 peptidomimetic
JQ-E EZH2
JQ-1 BET bromodomain
KD025 ROCK2
Ibrutinib BTK, ITK
Fostamatinib SYK
ICOS indicates inducible T cell costimulator; ROCK2, Rho-associated
kinase 2.
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drug targeting approaches based upon preventing effective
TFH-GC interactions (Table 1). As many of these reagents
have been tested in patients, these data lay the foundation
for repurposing such reagents to treat steroid-refractory
cGVHD in the clinic.
B CELLeDIRECTED THERAPY FOR TREATMENT AND
PREVENTION OF CHRONIC GVHD
Standard immune-suppressive therapies for established
cGVHD have primarily targeted the Tcell compartment. With
this approach, responses tend to be incomplete, and the
toxicity of long-term administration of corticosteroids is
prohibitive. Second-line antieT cell therapy results in even
poorer outcomes. The ﬁrst anecdotal evidence that targeting
B cells could be effective in the treatment of established
GVHD was provided by Ratanatharathorn et al. [78], and
Miklos et al. [4,79] were the ﬁrst to associate the formation of
speciﬁc anti-HY antibodies in a sex-mismatched model with
the occurrence of cGVHD (and protection from relapse).
Since then, a number of B celledependent processes have
been implicated in the pathogenesis of cGVHD, and
numerous clinical studies have provided evidence that tar-
geting B cells can be effective in the management of and
prevention of cGVHD.
Treatment of Corticosteroid-Refractory cGVHD
Several groups have reported the consistent effectiveness
of B cell depletion as therapy for established advanced
cGVHD [80]. In a review of the published literature on the
effectiveness of rituximab for the treatment of
corticosteroid-refractory cGVHD, response rates ranging
from 43% to 83% were reported with a pooled overall
response rate of 66% (95% conﬁdence interval [CI], 57% to
74%) [81]. Common to all reported studies, rituximab
administration in subjects with established cGVHD is rela-
tively safe with a low incidence of adverse events. However,
long-term replacement immunoglobulin therapy is often
required. There appears to be a predilection for higher
response rates in individuals with sclerodermatous or
lichenoid cutaneous disease [82] and so a randomized trial
comparing rituximab with imatinib, another agent with
activity against cutaneous sclerosis, has recently been
completed by the Chronic GVHD Consortium.
Initial Therapy of cGVHD
Sahaf et al. performed a pilot study of rituximab in com-
bination with corticosteroids as initial therapy of cGVHD
[83]. Thirty-ﬁve subjects with new-onset cGVHD whorequired corticosteroid treatment received 4 weekly in-
fusions of rituximab (375 mg/m2/week) in combination with
prednisone (1 mg/kg/day). A second course was allowed for
incomplete responses. Response, deﬁned as a complete or
partial response with a prednisone dose of <.25 mg/kg/day,
was noted in 40% of subjects at 6 and 12 months, suggesting
promising but incomplete activity. Although there were 6
deaths from cGVHD within 12 months of rituximab therapy,
only 2 subjects suffered a relapse of their malignancy [83]. In
this trial, cGVHD responses were predicted by a naïve
(CD19þCD38IgDþCD27-) B cell phenotype (P ¼ .03). Fifteen
cGVHD subjects included had undergone female to male
(F/M) HSCT, and 6 (38%) were H-Y IgM positive whereas 9
(56%) were IgG positive at cGVHD diagnosis. Among the 15
female to male HSCT recipients with cGVHD treated with
rituximab, 11 responded, and both H-Y IgM and IgG became
undetectable for at least 6 months after rituximab. In
contrast, the 4 F/M subjects who did not respond remained
H-Y IgG positive. Moreover, 2 subjects who redeveloped H-Y
IgG later had recurrent cGVHD. This suggests that either the
allo-reactive B cell or the antibodies elucidated by plasma
cell derivatives from these cells may actually be pathogenic.
Prevention of cGVHD
Given the promising role for B cell depletion as therapy
for established cGVHD, we explored the utility of rituximab
therapy for primary prevention of cGVHD [57]. In a phase II
trial, rituximab (375 mg/m2) was administered at 100 days
and 6, 9, and 12 months after HSCT to 65 subjects without
evidence of cGVHD at study onset. The cumulative incidence
of cGVHD and systemic corticosteroid-requiring cGVHD at
2 years from HCT were 48% and 31%, respectively, lower than
rates in a concurrent control cohort (60%, P ¼ .10 and 48.5%,
P ¼ .015, respectively). In related donors, the incidence of
cGVHD and corticosteroid-requiring cGVHD at 2 years was
35% and 23%, whereas the corresponding incidence in
unrelated donors was 59% and 38%. Rituximabwas safe, with
no severe infusion-related events and a 2-year cumulative
incidence of grade 3 to 5 infections of 15%. There was no
difference in relapse incidence (34% versus 28%, P ¼ .79), but
treatment-related mortality at 4 years from HSCT was
signiﬁcantly lower in rituximab-treated subjects when
compared with controls (5.1% versus 19.0%, P ¼ .02), and
overall survival was superior at 4 years (71% versus 56%,
P ¼ .05). In a multivariable regression model, only rituximab
use (hazard ratio, .56; 95% CI, .31 to 1.00; P ¼ .048) and high/
very high disease risk index (hazard ratio, 1.90; 95% CI, 1.02 to
3.53; P ¼ .04) were signiﬁcantly associated with overall
survival. B cell leukopenia was profound and persisted
through 18 months from HSCT, when evidence of B cell
reconstitution was evident in some subjects. The BAFF to B
cell ratio was signiﬁcantly higher in cGVHD subjects in
comparison with cGVHD-free subjects at 2 years (P ¼ .039).
This trial included 13 F/M recipients, none of whom
developed anti-DBYantibodies between 6months and 1 year
from HSCT, whereas 4 of 10 F/M control recipients devel-
oped anti-DBY antibodies in the same time period (P ¼ .02).
In a similar experience, Arai et al. also tested the role of
rituximab as primary prevention of cGVHD after HSCT using
a total lymphoid irradiation (TLI)/antithymocyte globulin
(ATG) preparative regimen [84]. In a small trial of 35 subjects,
rituximab (375 mg/m2) was infused weekly on days 56, 63,
70, and 77 after HSCT. The cumulative incidence of cGVHD
was 20%, which is slightly lower than the published rates of
cGVHD after TLI/ATG based transplantation [85]. In 10 F/M
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tion of allo-reactive H-Y antibody development, and none of
these subjects developed cGVHD. In comparison, among
25 F/M HCT patients who used the same TLI/ATG condi-
tioning regimen but without prophylactic rituximab during
this time period,14 of the 25 (56%) developed H-Yantibodies,
with 13 of the 25 (52%) developing cGVHD (P ¼ .01).
Most recently, Glass et al. reported the results of a ran-
domized trial in which 42 subjects with non-Hodgkin lym-
phoma were randomized to receive rituximab (375 mg/m2)
on 8 separate days between weeks 3 and 28 after trans-
plantation [86]. Thirty-six subjects actually received 1 or
more doses, but in an intention-to-treat analysis, there was
no difference in the incidence of cGVHD (33% in rituximab-
treated patients versus 41% in control patients, P ¼ .28).
However, in this trial, ATG was used, reducing the global
rates of cGVHD, and the relapse rate was high early after
transplantation (10 subjects in each group relapsed at a
median of 88 days and 90 days in the rituximab and control
groups, respectfully), making a competing risk cumulative
risk analysis less statistically powerful to detect differences.
Earlier attempts to prevent GVHD in single-arm studies
(generally to prevent acute GVHD, reviewed in Kharfan-
Dabaja and Cutler [7]) as well as a recent experience with B
cell depletion to prevent Epstein-Barr virus reactivation [87],
did not demonstrate a marked effect on the incidence of
cGVHD; however, in the majority of these experiences, B cell
depletion was administered early in the peri-transplantation
period, before active B cell reconstitution.CONCLUSIONS AND OTHER CONSIDERATIONS
AntieB cell therapy has been ﬁrmly established as being
partially effective in the treatment of established cGVHD and
recent studies suggest that antieB cell therapymayalso playa
role in the primary prevention of cGVHD. However, control
and prevention with anti-CD20 monoclonal antibody, ritux-
imab, is incomplete, and novel strategies are required to
improve outcomes and prevent the recurrent cGVHD that can
occur with B cell reconstitution. Novel second generation
anti-CD20monoclonal antibodiesmayprovidemoreeffective
B cell depletion and elimination of pathogenic allo- and auto-
reactive antibodies in vivo. However, as demonstrated in
preclinical models, small molecule inhibitors that target the
BCR signaling complexmay bemore effective than rituximab.
Clinical studies evaluating this approach will require testing
in prospective clinical trials and have recently begun. Addi-
tionally, antieB cell therapy in combination with T
celledirected therapies may ultimately be the most effective
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